ASS1 and cancer: Given the demonstrated efficacy of arginine deprivation therapy with pegargiminase in other cancer types and the identification of a significant patient subgroup with ASS1 deficiency in esophageal adenocarcinoma, clinical trials are warranted to evaluate the potential benefit of this therapy in this context.